- Home
- BEPC vs JAZZ Comparison
BEPC vs JAZZ Comparison
Compare BEPC & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEPC
- JAZZ
- Stock Information
- Founded
- BEPC 2019
- JAZZ 2003
- Country
- BEPC United States
- JAZZ Ireland
- Employees
- BEPC N/A
- JAZZ N/A
- Industry
- BEPC Electric Utilities: Central
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- BEPC Utilities
- JAZZ Health Care
- Exchange
- BEPC Nasdaq
- JAZZ Nasdaq
- Market Cap
- BEPC 6.1B
- JAZZ 6.7B
- IPO Year
- BEPC N/A
- JAZZ 2007
- Fundamental
- Price
- BEPC $36.43
- JAZZ $118.23
- Analyst Decision
- BEPC Buy
- JAZZ Strong Buy
- Analyst Count
- BEPC 3
- JAZZ 12
- Target Price
- BEPC $33.67
- JAZZ $183.00
- AVG Volume (30 Days)
- BEPC 898.1K
- JAZZ 636.6K
- Earning Date
- BEPC 08-01-2025
- JAZZ 08-04-2025
- Dividend Yield
- BEPC 4.09%
- JAZZ N/A
- EPS Growth
- BEPC N/A
- JAZZ 49.21
- EPS
- BEPC N/A
- JAZZ 7.51
- Revenue
- BEPC $3,923,000,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- BEPC $44.37
- JAZZ $6.00
- Revenue Next Year
- BEPC $7.44
- JAZZ $4.85
- P/E Ratio
- BEPC N/A
- JAZZ $15.74
- Revenue Growth
- BEPC N/A
- JAZZ 5.76
- 52 Week Low
- BEPC $23.73
- JAZZ $95.49
- 52 Week High
- BEPC $36.96
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- BEPC 67.99
- JAZZ 65.45
- Support Level
- BEPC $35.86
- JAZZ $115.92
- Resistance Level
- BEPC $36.96
- JAZZ $119.48
- Average True Range (ATR)
- BEPC 0.80
- JAZZ 2.88
- MACD
- BEPC 0.14
- JAZZ 0.71
- Stochastic Oscillator
- BEPC 87.72
- JAZZ 89.25
About BEPC Brookfield Renewable Corporation
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.